| # | Title | Journal | Year | Citations |
|---|
| 1 | Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group | Journal of Clinical Oncology | 2003 | 261 |
| 2 | Surgery in reference centers improves survival of sarcoma patients: a nationwide study | Annals of Oncology | 2019 | 191 |
| 3 | Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial | Nature Medicine | 2021 | 85 |
| 4 | Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor | Annals of Oncology | 2019 | 72 |
| 5 | Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’ | Annals of Oncology | 2018 | 67 |
| 6 | Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial | Lancet Oncology, The | 2019 | 57 |
| 7 | Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’ | European Journal of Cancer | 2020 | 42 |
| 8 | Immunological and classical subtypes of oral premalignant lesions | OncoImmunology | 2018 | 35 |
| 9 | Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study | British Journal of Cancer | 2019 | 33 |
| 10 | Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma | OncoImmunology | 2020 | 31 |
| 11 | Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial | European Journal of Cancer | 2013 | 30 |
| 12 | Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study | Annals of Surgical Oncology | 2020 | 28 |
| 13 | Beyond the map: evidencing the spatial dimension of health inequalities | International Journal of Health Geographics | 2020 | 28 |
| 14 | Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy | International Journal of Radiation Oncology Biology Physics | 2018 | 27 |
| 15 | Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond | Cancers | 2022 | 25 |
| 16 | Very long‐term survivors among patients with metastatic soft tissue sarcoma | Cancer Medicine | 2019 | 16 |
| 17 | Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients | European Journal of Cancer | 2022 | 14 |
| 18 | Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report | Immunotherapy | 2018 | 11 |
| 19 | PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles’ heel? | Clinics and Research in Hepatology and Gastroenterology | 2021 | 11 |
| 20 | A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome | Scientific Reports | 2017 | 10 |
| 21 | Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study | Annals of Surgical Oncology | 2020 | 10 |
| 22 | The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments | Expert Review of Anticancer Therapy | 2020 | 10 |
| 23 | Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality? | Future Oncology | 2019 | 6 |
| 24 | Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM) | Cancer | 2022 | 4 |
| 25 | Foreword | Expert Review of Anticancer Therapy | 2020 | 1 |
| 26 | Sarcoma management: expertise and balance | Future Oncology | 2021 | 1 |
| 27 | Keeping the balance, the true major goal in advanced sarcoma | Future Oncology | 2021 | 1 |
| 28 | Distinct Cellular Origins and Differentiation Process Account for Distinct Oncogenic and Clinical Behaviors of Leiomyosarcomas | Cancers | 2023 | 1 |
| 29 | Driving forward: beneficial treatment strategies for leiomyosarcoma patients | Future Oncology | 0 | 0 |
